Roche reports phase III CENTERSTONE study of Xofluza significantly decreases the transmission of influenza viruses

Roche has announced positive topline results from the phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral drug that significantly reduces the transmission of influenza viruses. The study achieved its primary endpoint, showing that a single oral dose of Xofluza taken by infected individuals greatly lowered the chances of virus transmission to others in their households. Xofluza was well tolerated, with no new safety concerns identified.

The CENTERSTONE study, the first global phase III trial to demonstrate a transmission reduction benefit for an antiviral against a respiratory virus, involved over 4,000 participants and was partially funded by the US Department of Health and Human Services. It investigated the efficacy of Xofluza when administered within 48 hours of symptom onset.

With influenza responsible for an estimated one billion infections and up to 650,000 deaths annually worldwide, the effective management of influenza is critical for public health.